G

    GRI Bio Inc. (GRI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.92
    +0.00 (+0.00%)

    Market Cap: $4.20M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(10/13)
    Avg Surprise
    -2.25%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.93
    Range$-0.93 - $-0.93
    1 analysts
    EPS RevisionsNo revisions (7d)
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.95-2.2%
    60d ago$-1.08-16.1%
    30d ago$-1.08-16.1%
    7d ago$-1.08-16.1%
    Current$-0.93
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.74
    Range$1.74 - $1.74
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.74---
    Sep 26EST
    		-$-0.93---
    Jun 26
    Reported Aug 13
    		$-0.91$-1.20+24.17%Beat+97.5%
    Mar 26
    Reported May 13
    		$-1.61N/A+56.95%Beat+72.2%
    Dec 25
    Reported Mar 13
    		$-116.61$-29.26-298.53%Miss-1487.9%
    Sep 25
    Reported Nov 14
    		$-35.84$-31.08-15.32%Miss+88.8%
    Jun 25
    Reported Aug 14
    		$-36.68$-36.68+0.00%Beat-646.2%
    Mar 25
    Reported May 15
    		$-5.80N/A+94.53%Beat-86.9%
    Dec 24
    Reported Mar 26
    		$-7.34$-5.44-35.00%Miss-136.6%
    Sep 24
    Reported Nov 14
    		$-318.92$-347.48+8.22%Beat-61455.7%
    Jun 24
    Reported Aug 13
    		$-4.92N/AN/ABeat+99.9%
    Mar 24
    Reported May 10
    		$-3.10N/AN/ABeat+41.8%
    Dec 23
    Reported Feb 22
    		$-3.10N/AN/ABeat-2486.2%
    Sep 23
    Reported Nov 14
    		$-0.52N/AN/ABeat-475.7%
    Jun 23
    Reported Aug 14
    		$-4316.37N/AN/ABeat-2158086.5%
    Mar 23
    Reported May 15
    		$-5.33$0.00N/AMiss-2323.4%
    Dec 22
    Reported Feb 24
    		$-0.12N/A+58.62%Beat+45.5%
    Sep 22
    Reported Nov 3
    		$-0.09N/A+64.00%Beat+50.0%
    Jun 22
    Reported Jul 28
    		$-0.20$-0.23+13.04%Beat+41.2%
    Mar 22
    Reported Jun 29
    		$-0.22$-0.22+0.00%Beat+52.2%
    Dec 21
    Reported Mar 30
    		$-0.22$-0.22+0.00%Beat-57.1%
    Sep 21
    Reported Nov 12
    		$-0.18$0.00N/AMiss+5.3%
    Jun 21
    Reported Sep 1
    		$-0.34$0.00N/AMiss-
    Mar 21
    Reported Jun 29
    		$-0.46$0.00N/AMiss-
    Dec 20
    Reported Mar 30
    		$-0.14$0.00N/AMiss-
    Sep 20
    Reported Oct 23
    		$-0.19$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-142.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.30xQuick Ratio10.30x
    Trading Statistics
    Beta-0.66Avg Volume406.74K
    52-Week High$80.3652-Week Low$1.36

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.83
    SMA 20$1.77
    SMA 50$1.70
    SMA 200$8.03
    EMA 10$1.87
    EMA 20$1.79
    EMA 50$1.84
    EMA 200$14.76

    MACD

    Line: 0.07Signal: 0.05Hist: 0.03

    ADX

    ADX: 37.5+DI: 30.5-DI: 12.7

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down16.0
    PSAR$2.38

    Bollinger Bands

    Upper Band$2.15
    Lower Band$1.40
    %B Position4272%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    56.0

    Momentum Oscillators

    Stoch %K46.0
    Stoch %D46.2
    Williams %R-49.2
    ROC (10d)11.0%
    Momentum0.19
    CCI (20d)61.9
    MFI (14d)36.5

    Volatility Measures

    ATR (14d)$0.17(9.0%)
    StdDev (20d)0.19
    Hist Vol152.7%(High)

    Volume Flow

    VWAP$1.92
    OBV39.4M
    AD Line1867533418142.4B
    CMF (20d)0.045

    Volume Metrics

    Avg Vol (20d)426.0K
    Vol Ratio0.1x(Low)
    VWMA (20d)$2.11

    Pivot Points

    R3$2.18
    R2$2.13
    R1$2.02
    Pivot Point$1.97
    S1$1.86
    S2$1.81
    S3$1.70

    Advanced Oscillators

    TSI10.85
    Ultimate Osc51.9
    KST170.39

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2.30M$0$0$0$5.39M$0
    Cost of Revenue$0$0$1,000$0$0$0$1,000$0$0$0$15,000$0
    Gross Profit$0$0$-1,000$0$0$0$-1,000$0$0$0$-15,000$0
    Operating Expenses$1.65M$2.00M$2.66M$3.37M$2.90M$3.05M$1.95M$2.13M$2.26M$1.90M$2.03M$2.44M
    R&D$407,000$361,000$1.53M$1.77M$1.88M$1.64M$833,000$1.13M$877,000$933,000$1.05M$1.19M
    SG&A$1.24M$1.64M$1.13M$1.60M$1.02M$1.41M$1.12M$1.00M$1.38M$962,000$979,000$1.25M
    Operating Income$-1,648,000$-2,003,000$-2,664,000$-3,365,000$-2,897,000$-3,051,000$-1,953,000$-2,130,000$-2,257,000$-1,895,000$-2,026,000$-2,439,000
    Interest Income$5,000$5,000$5,000$6,000$5,000$5,000$6,000$7,000$6,000$6,000$8,000$6,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$228,000$0
    Income Before Tax$-1,643,000$-1,998,000$-2,659,000$-3,359,000$-2,892,000$-3,046,000$-1,947,000$-2,123,000$-2,250,000$-1,887,000$-2,254,000$-2,137,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,643,000$-1,998,000$-2,659,000$-3,359,000$-2,892,000$-3,046,000$-1,947,000$-2,123,000$-2,250,000$-1,887,000$-2,004,000$-2,137,000
    EBITDA$-1,648,000$-2,002,000$-2,663,000$-3,364,000$-2,896,000$-3,050,000$-1,952,000$-2,129,000$-2,255,000$-1,892,000$-2,261,000$-2,142,000
    EBIT$-1,648,000$-2,003,000$-2,664,000$-3,365,000$-2,897,000$-3,051,000$-1,953,000$-2,130,000$-2,256,000$-1,893,000$-2,262,000$-2,143,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GRI

    News

    GRI Bio will present four sets of data on a potential lung-scarring treatment at ERS 2026

    GRI Bio (NASDAQ: GRI) announced that four presentations, including a late-breaking oral presentation, from its Phase 2a GRI-0621-IPF-02 trial for idiopathic pulmonary fibrosis (IPF) have been accepted for the 2026 European Respiratory Society Congress. The data will highlight the safety, tolerability, lung function, and anti-fibrotic biomarker profiles of GRI-0621. This news led to an 8.48% increase in GRI's stock price during the August 24 session.

    Stock Titan•8/25/26•
    Neutral

    GRI Bio to present Phase 2a IPF drug data at ERS Congress

    GRI Bio, Inc. (NASDAQ:GRI) announced it will present data from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis (IPF) at the 2026 European Respiratory Society Congress. The presentations will include one late-breaking oral presentation and three poster presentations, covering safety, tolerability, biomarker profiles, and lung function outcomes of the oral retinoic acid receptor β/γ-selective agonist. GRI-0621 is designed to modulate pathways associated with inflammation, fibrosis, and tissue repair in IPF, a progressive fibrotic lung disease.

    Investing.com•8/24/26•
    Bullish

    GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data

    GRI Bio announced that three abstracts and an oral presentation detailing data from the Phase 2a GRI-0621-IPF-02 study will be presented at the 2026 European Respiratory Society (ERS) Congress. The presentations will cover the safety, tolerability, translational biomarker profile, and potential impact on lung function of GRI-0621, an oral retinoic acid receptor (RAR) β/γ-selective agonist for idiopathic pulmonary fibrosis (IPF). CEO Marc Hertz highlighted encouraging and complementary signals supporting GRI-0621's differentiated mechanism and potential to address the underlying biology of IPF.

    GlobeNewswire•8/24/26•
    Bullish

    GRI Bio Inc. (NASDAQ: GRI) Share Price, GRI Stock News, GRI Share Price & Updates

    GRI Bio Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead product candidate, GRI-0621, is in Phase IIa clinical trials for idiopathic pulmonary fibrosis, and it also has GRI-0803 in preclinical development for autoimmune disorders. The article provides key financial metrics, income statements, balance sheets, and cash flow breakdowns for the company, alongside a peer comparison in the biotechnology sector.

    kalkine.ca•8/22/26•
    Neutral

    GRI Bio, Inc. 2Q 2026: Net income $(1.64)M, EPS $(0.91) — 10-Q Summary

    GRI Bio, Inc. reported a net loss of $(1.64)M and diluted EPS of $(0.91) for Q2 2026, with no operating revenue. The company successfully completed a Phase 2a trial for GRI-0621, which met its primary safety endpoint and showed promising biomarker activity, leading to FDA Orphan Drug Designation for idiopathic pulmonary fibrosis. Although recent financing extends cash runway into Q2 2027, additional funding is required for further clinical trials and the development of GRI-0803.

    TradingView•8/14/26•
    Neutral

    Frequently Asked Questions About GRI

    Does GRI pay dividends?
    GRI Bio Inc. (GRI) does not currently pay a regular dividend.
    What is GRI's market cap?
    GRI Bio Inc. (GRI) has a market capitalization of $4.20M with a current stock price of $1.92.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In